TRIM5αrh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages

Joseph S Anderson, Ramesh Akkina

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Species-specific innate resistance against viral infections offers novel avenues for antiviral therapeutic and prophylactic approaches. The retroviral and lentiviral restriction factors Ref1 and Lv1 are variants of the tripartite motif protein TRIM5α, a component of cytoplasmic bodies. TRIM5α severely restricts productive retroviral infections at the postentry and preintegration steps by destabilizing the incoming viral capsid via ubiquitination. Using this approach, resistance to HIV-1 infection could be conferred by TRIM5αrh expression in otherwise susceptible cells. Here we show that stable expression of simian TRIM5αrh via a lentiviral vector in a permissive cell culture line, Magi-CXCR4, conferred resistance to HIV-1. To translate these findings into a stem cell gene therapy setting, the TRIM5αrh transgene was stably introduced into CD34+ hematopoietic progenitor cells to derive transgenic macrophages. Upon viral challenge, TRIM5αrh -expressing macrophages were highly resistant to HIV-1 infection compared to control cells. Human macrophages expressing TRIM5αrh were also found to be phenotypically and functionally normal, expressing the characteristic surface markers CD14, CD4, CCR5, CXCR4, MHC II, and B7.1. These results demonstrate that the species-specific restriction factor TRIM5αrh is effective in conferring HIV-1 resistance in a stem cell setting, thus paving the way for its application in AIDS gene therapy.

Original languageEnglish (US)
Pages (from-to)687-696
Number of pages10
JournalMolecular Therapy
Volume12
Issue number4
DOIs
StatePublished - Oct 2005
Externally publishedYes

Fingerprint

HIV Infections
HIV-1
Macrophages
Genetic Therapy
Stem Cells
Capsid
Ubiquitination
Virus Diseases
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Transgenes
Antiviral Agents
Acquired Immunodeficiency Syndrome
Cell Culture Techniques
Cell Line
Infection
Therapeutics

Keywords

  • HIV-1 restriction
  • HIV/AIDS gene therapy
  • Lentiviral vector
  • Retroviral restriction
  • Transgenic macrophages
  • TRIM5α

ASJC Scopus subject areas

  • Molecular Biology

Cite this

TRIM5αrh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages. / Anderson, Joseph S; Akkina, Ramesh.

In: Molecular Therapy, Vol. 12, No. 4, 10.2005, p. 687-696.

Research output: Contribution to journalArticle

@article{c561e1f0090c4ba1a5190b54ddb2c829,
title = "TRIM5αrh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages",
abstract = "Species-specific innate resistance against viral infections offers novel avenues for antiviral therapeutic and prophylactic approaches. The retroviral and lentiviral restriction factors Ref1 and Lv1 are variants of the tripartite motif protein TRIM5α, a component of cytoplasmic bodies. TRIM5α severely restricts productive retroviral infections at the postentry and preintegration steps by destabilizing the incoming viral capsid via ubiquitination. Using this approach, resistance to HIV-1 infection could be conferred by TRIM5αrh expression in otherwise susceptible cells. Here we show that stable expression of simian TRIM5αrh via a lentiviral vector in a permissive cell culture line, Magi-CXCR4, conferred resistance to HIV-1. To translate these findings into a stem cell gene therapy setting, the TRIM5αrh transgene was stably introduced into CD34+ hematopoietic progenitor cells to derive transgenic macrophages. Upon viral challenge, TRIM5αrh -expressing macrophages were highly resistant to HIV-1 infection compared to control cells. Human macrophages expressing TRIM5αrh were also found to be phenotypically and functionally normal, expressing the characteristic surface markers CD14, CD4, CCR5, CXCR4, MHC II, and B7.1. These results demonstrate that the species-specific restriction factor TRIM5αrh is effective in conferring HIV-1 resistance in a stem cell setting, thus paving the way for its application in AIDS gene therapy.",
keywords = "HIV-1 restriction, HIV/AIDS gene therapy, Lentiviral vector, Retroviral restriction, Transgenic macrophages, TRIM5α",
author = "Anderson, {Joseph S} and Ramesh Akkina",
year = "2005",
month = "10",
doi = "10.1016/j.ymthe.2005.07.291",
language = "English (US)",
volume = "12",
pages = "687--696",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - TRIM5αrh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages

AU - Anderson, Joseph S

AU - Akkina, Ramesh

PY - 2005/10

Y1 - 2005/10

N2 - Species-specific innate resistance against viral infections offers novel avenues for antiviral therapeutic and prophylactic approaches. The retroviral and lentiviral restriction factors Ref1 and Lv1 are variants of the tripartite motif protein TRIM5α, a component of cytoplasmic bodies. TRIM5α severely restricts productive retroviral infections at the postentry and preintegration steps by destabilizing the incoming viral capsid via ubiquitination. Using this approach, resistance to HIV-1 infection could be conferred by TRIM5αrh expression in otherwise susceptible cells. Here we show that stable expression of simian TRIM5αrh via a lentiviral vector in a permissive cell culture line, Magi-CXCR4, conferred resistance to HIV-1. To translate these findings into a stem cell gene therapy setting, the TRIM5αrh transgene was stably introduced into CD34+ hematopoietic progenitor cells to derive transgenic macrophages. Upon viral challenge, TRIM5αrh -expressing macrophages were highly resistant to HIV-1 infection compared to control cells. Human macrophages expressing TRIM5αrh were also found to be phenotypically and functionally normal, expressing the characteristic surface markers CD14, CD4, CCR5, CXCR4, MHC II, and B7.1. These results demonstrate that the species-specific restriction factor TRIM5αrh is effective in conferring HIV-1 resistance in a stem cell setting, thus paving the way for its application in AIDS gene therapy.

AB - Species-specific innate resistance against viral infections offers novel avenues for antiviral therapeutic and prophylactic approaches. The retroviral and lentiviral restriction factors Ref1 and Lv1 are variants of the tripartite motif protein TRIM5α, a component of cytoplasmic bodies. TRIM5α severely restricts productive retroviral infections at the postentry and preintegration steps by destabilizing the incoming viral capsid via ubiquitination. Using this approach, resistance to HIV-1 infection could be conferred by TRIM5αrh expression in otherwise susceptible cells. Here we show that stable expression of simian TRIM5αrh via a lentiviral vector in a permissive cell culture line, Magi-CXCR4, conferred resistance to HIV-1. To translate these findings into a stem cell gene therapy setting, the TRIM5αrh transgene was stably introduced into CD34+ hematopoietic progenitor cells to derive transgenic macrophages. Upon viral challenge, TRIM5αrh -expressing macrophages were highly resistant to HIV-1 infection compared to control cells. Human macrophages expressing TRIM5αrh were also found to be phenotypically and functionally normal, expressing the characteristic surface markers CD14, CD4, CCR5, CXCR4, MHC II, and B7.1. These results demonstrate that the species-specific restriction factor TRIM5αrh is effective in conferring HIV-1 resistance in a stem cell setting, thus paving the way for its application in AIDS gene therapy.

KW - HIV-1 restriction

KW - HIV/AIDS gene therapy

KW - Lentiviral vector

KW - Retroviral restriction

KW - Transgenic macrophages

KW - TRIM5α

UR - http://www.scopus.com/inward/record.url?scp=25144460493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144460493&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2005.07.291

DO - 10.1016/j.ymthe.2005.07.291

M3 - Article

C2 - 16081321

AN - SCOPUS:25144460493

VL - 12

SP - 687

EP - 696

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 4

ER -